- HeartSciences Inc. and Front Range Ventures LLC entered into Amendment No. 7 to their Loan and Security Agreement and a No. 3 Amended and Restated Secured Promissory Note on **September 26, 2025**, extending the maturity date of the **$500,000** loan to **September 30, 2026**, with an interest rate of **12% per annum, compounded annually**.  **[1468492_0001193125-25-227023_hscs-ex10_1.htm:0]** **[1468492_0001193125-25-227023_hscs-20250926.htm:1]** 
- As of **October 1, 2025**, the company received **$6.7 million** in gross proceeds from its Regulation A Offering, resulting in the issuance of **1,912,383 Units**.  **[1468492_0001193125-25-227023_hscs-20250926.htm:3]** 
- Also as of **October 1, 2025**, HeartSciences Inc. completed a debt exchange, converting **$2,060,000 in principal** and **$45,000 of accrued interest** from an unsecured promissory note into **597,578 shares of common stock**.  **[1468492_0001193125-25-227023_hscs-20250926.htm:3]** 
- Following these transactions, there are **3,069,635 shares of common stock** issued and outstanding as of **October 1, 2025**.  **[1468492_0001193125-25-227023_hscs-20250926.htm:3]**

HeartSciences Inc. extends loan maturity, raises capital, and converts debt

- HeartSciences Inc. reported **no meaningful revenue** for the first quarter of fiscal 2026, which ended **July 31, 2025**.  **[1468492_0001468492-25-000011_hscs-ex99_1.htm:1]** 
- As of **July 31, 2025**, the company had approximately **$2.8 million in cash and cash equivalents** and **$3.1 million in shareholders’ equity**.  **[1468492_0001468492-25-000011_hscs-ex99_1.htm:1]** 
- The company successfully launched its **MyoVista Insights™ software platform** and received an **FDA Breakthrough Device Designation** for its aortic stenosis ECG algorithm.  **[1468492_0001468492-25-000011_hscs-ex99_1.htm:0]** **[1468492_0001468492-25-000011_hscs-ex99_1.htm:1]** 
- Subsequent to the quarter, HeartSciences strengthened its balance sheet by raising an additional **$0.8 million** through a Reg A+ offering and converting **$0.7 million of debt into equity**.  **[1468492_0001468492-25-000011_hscs-ex99_1.htm:1]**

HeartSciences Reports Q1 2026 Financial Results and Business Updates

- HeartSciences reported **no meaningful revenue** for the first quarter of fiscal 2026, which ended **July 31, 2025**. As of that date, the company had approximately **$2.8 million in cash** and cash equivalents, and **$3.1 million in shareholders’ equity**.  **[1468492_84ef7ef00d464748a93544f699706f5e_2]** 
- Subsequent to FQ1 2026, HeartSciences raised an additional **$0.8 million** through its Reg A+ offering and exchanged **$0.7 million** of debt into equity.  **[1468492_84ef7ef00d464748a93544f699706f5e_2]** 
- The company successfully launched **MyoVista Insights**, a cloud-native software platform designed for AI-ECG algorithms, and received **FDA Breakthrough Device Designation** for its aortic stenosis ECG algorithm.  **[1468492_84ef7ef00d464748a93544f699706f5e_0]** **[1468492_84ef7ef00d464748a93544f699706f5e_1]** 
- **CPT reimbursement codes** are now in place for AI-ECG, covering algorithms provided by MyoVista Insights, which is expected to support AI-ECG adoption.  **[1468492_84ef7ef00d464748a93544f699706f5e_0]**

HeartSciences (HSCS)